JPMorgan Reinstates Teva Pharma (TEVA) at Overweight

JPMorgan reinstated coverage on Teva Pharma (NYSE: TEVA) with an Overweight rating and a price target of $82.00 (prior $70.00).

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $69.02 yesterday.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR18 at JPMorgan
• RLJ Lodging Trust (RLJ) PT Raised to $10 at Truist Securities